The HFSA Virtual Annual Scientific Meeting 2020 will feature two late breaking clinical trial sessions and three solo sessions dedicated to updates on significant trials. Explore session titles and speakers below: 

Late Breaking Clinical Trials Session 1

Saturday, October 3, 4:30 PM – 5:30 PM

• Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results from the Help-ph-hfpef Multicenter Randomized Controlled Trial
  – Barry Borlaug, MD, Mayo Clinic

• Mechanistic Insight Into the effect of Spironolactone for Preventing Heart Failure: Proteomics and Knowledge-Based Network Analysis from the Homage Trial
  – Joao Pedro Ferreira, MD, PhD, CIC-P Nancy

• Excess 30-Day Heart Failure Readmission In Blacks Increases with Neighborhood Deprivation
  – Shivani Patel, MPH, PhD, Emory University

• Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)
  – John McMurray, MD, Institute of Cardiovascular and Medical Sciences

• Kidney Function After Initiation and Discontinuation of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights from the Emperial Trials
  – Stefan Anker, MD, Charité University
   

Late Breaking Clinical Trials Session 2

Monday October 5, 6:00 PM – 7:00 PM

• Main Results of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients with Heart Failure Trial
  – Mikhail Kosiborod, MD, Saint Luke's Mid America Heart Institute

• Effect of Vericiguat In Victoria According to Guideline-Directed Medical Therapy
  – Justin Ezekowitz, MD, CVC, University of Alberta

• A Randomized Trial Comparing the Effect of Sacubitril/Valsartan to Valsartan On Left Ventricular Remodeling In Patients with Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction
  – Kieran Docherty, MBChB, Institute of Cardiovascular and Medical Sciences University of Glasgow

• Endovascular Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction - First-in-Human Clinical Trial
  – Sanjiv Shah, MD, Northwestern University, Feinberg School of Medicine

• Effect of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients with Heart Failure with a Reduced Ejection Fraction, with and without Sacubitril/Valsartan
  – Milton Packer, MD, Baylor University Medical Center

Updates to Significant Trial Solo Sessions Include:

• EMPEROR Reduced – Saturday, October 3 
• DAPA-Heart Failure – One Year On – Sunday, October 4
• New Data and Learnings from VICTORIA Trial – Sunday, October 4